{"id":"18f-mfbg","safety":{"commonSideEffects":[]},"_chembl":{"chemblId":"CHEMBL4650354","moleculeType":"Small molecule","molecularWeight":"166.19"},"_dailymed":null,"mechanism":{"_ai_source":"claude-haiku-4.5","explanation":"18F-MFBG is a PET imaging agent that mimics norepinephrine and binds to norepinephrine transporters (NET) expressed on neuroendocrine tumor cells. This allows visualization and localization of NET-positive tumors such as pheochromocytoma, paraganglioma, and neuroblastoma. The fluorine-18 radiolabel enables high-resolution PET imaging for diagnostic and staging purposes.","oneSentence":"18F-MFBG is a fluorine-18 labeled radiopharmaceutical that targets norepinephrine transporters for positron emission tomography (PET) imaging of neuroendocrine tumors.","_ai_confidence":"medium"},"_scrapedAt":"2026-03-28T00:56:17.928Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Imaging of neuroendocrine tumors including pheochromocytoma and paraganglioma"},{"name":"Neuroblastoma imaging and staging"}]},"trialDetails":[{"nctId":"NCT07176286","phase":"PHASE2","title":"18F-mFBG Cardiac Uptake With Lewy Body Dementia","status":"RECRUITING","sponsor":"Innervate Radiopharmaceuticals LLC (Formerly: Illumina Radiopharmaceuticals LLC)","startDate":"2026-04-15","conditions":"Parkinson Disease (PD), Lewy Body Dementia (LBD)","enrollment":20},{"nctId":"NCT06965621","phase":"PHASE2","title":"18F-mFBG Imaging for Myocardial Sympathetic Innervation","status":"NOT_YET_RECRUITING","sponsor":"Innervate Radiopharmaceuticals LLC (Formerly: Illumina Radiopharmaceuticals LLC)","startDate":"2026-04-28","conditions":"Heart Failure, Ischemic Cardiomyopathy, ICD Patients","enrollment":20},{"nctId":"NCT06858501","phase":"PHASE2","title":"Comparing 123I-MIBG and 18F-MFBG Imaging in Patients With Newly Diagnosed, High Risk Neuroblastoma","status":"NOT_YET_RECRUITING","sponsor":"Children's Oncology Group","startDate":"2026-06-22","conditions":"Ganglioneuroblastoma, Ganglioneuroblastoma, Nodular, High Risk Neuroblastoma","enrollment":84},{"nctId":"NCT07195500","phase":"","title":"Clinical Application of Somatostatin Receptor and Norepinephrine Transporter Targeted Imaging for Diagnosis and Staging of Neuroblastoma and Pheochromocytoma/Paraganglioma","status":"RECRUITING","sponsor":"Nanjing First Hospital, Nanjing Medical University","startDate":"2024-12-25","conditions":"Neuroblastoma, Pheochromocytoma, Paraganglioma","enrollment":30},{"nctId":"NCT07111117","phase":"PHASE2","title":"Comparison of 18F Labeled Analog of MIBG (18F-MFBG) PET/CT and 123I-MIBG SPECT in Pediatric Patients With Neuroblastoma.","status":"NOT_YET_RECRUITING","sponsor":"Institut Curie","startDate":"2026-03-01","conditions":"Neuroblastoma","enrollment":30},{"nctId":"NCT06852807","phase":"","title":"18F-mFBG PET Imaging in the Evaluation of Neuroblastoma","status":"RECRUITING","sponsor":"First Affiliated Hospital of Zhejiang University","startDate":"2025-02-04","conditions":"Neuroblastoma","enrollment":200},{"nctId":"NCT06813742","phase":"","title":"18F-mFBG PET Imaging in the Evaluation of Pheochromocytoma","status":"RECRUITING","sponsor":"First Affiliated Hospital of Zhejiang University","startDate":"2023-05-01","conditions":"Pheochromocytoma","enrollment":80},{"nctId":"NCT04535193","phase":"PHASE1, PHASE2","title":"Open-Label Study of 18F-mFBG for Imaging Myocardial Sympathetic Innervation","status":"COMPLETED","sponsor":"Innervate Radiopharmaceuticals LLC (Formerly: Illumina Radiopharmaceuticals LLC)","startDate":"2021-11-05","conditions":"Cardiovascular Diseases","enrollment":10},{"nctId":"NCT04724369","phase":"PHASE3","title":"Open-Label Study of 18F-mFBG for Imaging Neuroblastoma","status":"COMPLETED","sponsor":"Innervate Radiopharmaceuticals LLC (Formerly: Illumina Radiopharmaceuticals LLC)","startDate":"2021-11-18","conditions":"Neuroblastoma","enrollment":43},{"nctId":"NCT02348749","phase":"PHASE1, PHASE2","title":"18F-MFBG Imaging for Evaluation of Neuroendocrine Malignancies","status":"COMPLETED","sponsor":"Memorial Sloan Kettering Cancer Center","startDate":"2015-01","conditions":"Neuroendocrine Tumors","enrollment":48},{"nctId":"NCT06120049","phase":"PHASE2, PHASE3","title":"[18F]-MFBG Versus [123I]-MIBG and [18F]-PE2I in PD vs. MSA and DLB vs. AD","status":"RECRUITING","sponsor":"prof. dr. Koen Van Laere","startDate":"2024-01-19","conditions":"Parkinson Disease, Dementia With Lewy Bodies, MSA - Multiple System Atrophy","enrollment":113},{"nctId":"NCT06233903","phase":"PHASE2","title":"18F-mFBG Expression in Neural Crest Tumors and Organs Innervated by the Sympathetic Nervous System","status":"WITHDRAWN","sponsor":"Innervate Radiopharmaceuticals LLC (Formerly: Illumina Radiopharmaceuticals LLC)","startDate":"2025-01","conditions":"Neuroblastoma, Pheochromocytoma, Paraganglioma","enrollment":""},{"nctId":"NCT05826158","phase":"NA","title":"18F-mFBG LAFOV PET/CT Compared to 123I-mIBG Scintigraphy SPECT/CT for Evaluation of Children With Neuroblastoma","status":"RECRUITING","sponsor":"Rigshospitalet, Denmark","startDate":"2022-06-06","conditions":"Neuroblastoma","enrollment":25},{"nctId":"NCT05069220","phase":"EARLY_PHASE1","title":"18F-MFBG PET/CT in the Evaluation of Neural Crest Tumor","status":"RECRUITING","sponsor":"Peking Union Medical College Hospital","startDate":"2021-09-01","conditions":"Neuroendocrine Tumor, Neuroblastoma, Pheochromocytoma","enrollment":150},{"nctId":"NCT06149195","phase":"","title":"18F-MFBG Cardiac Imaging for Heart Failure Administration","status":"ENROLLING_BY_INVITATION","sponsor":"Sichuan Provincial People's Hospital","startDate":"2024-01-01","conditions":"Rest Gated Myocardial Perfusion Imaging in Heart Failure","enrollment":100},{"nctId":"NCT04258592","phase":"PHASE1","title":"18F-MFBG PET Imaging of the Norepinephrine Transporter in Neural Crest and Neuroendocrine Tumors","status":"TERMINATED","sponsor":"Universitaire Ziekenhuizen KU Leuven","startDate":"2020-02-07","conditions":"Neural Crest Tumor, Neuroendocrine Tumors","enrollment":6}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":20,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":["Florbenguane F-18","meta-fluorobenzylguanidine","IRP101","18F-metafluorobenzylguanidine"],"phase":"phase_3","status":"active","brandName":"18F-MFBG","genericName":"18F-MFBG","companyName":"First Affiliated Hospital of Zhejiang University","companyId":"first-affiliated-hospital-of-zhejiang-university","modality":"Small molecule","firstApprovalDate":"","aiSummary":"18F-MFBG is a fluorine-18 labeled radiopharmaceutical that targets norepinephrine transporters for positron emission tomography (PET) imaging of neuroendocrine tumors. Used for Imaging of neuroendocrine tumors including pheochromocytoma and paraganglioma, Neuroblastoma imaging and staging.","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":2,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":false,"trials":true,"score":3}}